keyword
MENU ▼
Read by QxMD icon Read
search

Biotherapy

keyword
https://www.readbyqxmd.com/read/29310351/efficacy-and-safety-of-folfiri-and-biotherapy-versus-folfiri-alone-for-metastatic-colorectal-cancer-patients-a-meta-analysis
#1
Yangbo Jiang, Hui Fan, Yongmei Jiang, Guirong Song, Feng Wang, Xiaofeng Li, Guoquan Li
BACKGROUND: Previous randomized controlled trials (RCTs) and meta-analyses have demonstrated the useless of FOLFIRI alone for previously treated patients with metastatic colorectal cancer (mCRC). The role of FOLFIRI regimen combined with biological therapy is unknown. The purpose of this meta-analysis is to evaluate the efficacy and safety of combining biological therapy with chemotherapy in previously treated patients with mCRC. METHODS: MEDLINE, EMBASE, Web of Science, Cochrane library, and ClinicalTrials...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29229497/advanced-neuroendocrine-tumours-of-the-small-intestine-and-pancreas-clinical-developments-controversies-and-future-strategies
#2
REVIEW
Christoph J Auernhammer, Christine Spitzweg, Martin K Angele, Stefan Boeck, Ashley Grossman, Svenja Nölting, Harun Ilhan, Thomas Knösel, Julia Mayerle, Martin Reincke, Peter Bartenstein
In this Review, we discuss clinical developments and controversies in the treatment of neuroendocrine tumours (NETs) that are relevant for clinicians and clinical researchers. We describe advances in genetics, blood-based biomarkers, functional imaging, and systemic therapy of advanced NETs and discuss results of recent phase 3 studies, systemic treatment of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemotherapy, and molecularly targeted therapy, and the potential role of immunotherapy in the treatment of NETs...
December 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29202467/endothelial-chimerism-and-vascular-sequestration-protect-pancreatic-islet-grafts-from-antibody-mediated-rejection
#3
Chien-Chia Chen, Eric Pouliquen, Alexis Broisat, Francesco Andreata, Maud Racapé, Patrick Bruneval, Laurence Kessler, Mitra Ahmadi, Sandrine Bacot, Carole Saison-Delaplace, Marina Marcaud, Jean-Paul Duong Van Huyen, Alexandre Loupy, Jean Villard, Sandrine Demuylder-Mischler, Thierry Berney, Emmanuel Morelon, Meng-Kun Tsai, Marie-Nathalie Kolopp-Sarda, Alice Koenig, Virginie Mathias, Stéphanie Ducreux, Catherine Ghezzi, Valerie Dubois, Antonino Nicoletti, Thierry Defrance, Olivier Thaunat
Humoral rejection is the most common cause of solid organ transplant failure. Here, we evaluated a cohort of 49 patients who were successfully grafted with allogenic islets and determined that the appearance of donor-specific anti-HLA antibodies (DSAs) did not accelerate the rate of islet graft attrition, suggesting resistance to humoral rejection. Murine DSAs bound to allogeneic targets expressed by islet cells and induced their destruction in vitro; however, passive transfer of the same DSAs did not affect islet graft survival in murine models...
November 20, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29201454/the-role-of-peptide-receptor-radionuclide-therapy-in-advanced-metastatic-thoracic-neuroendocrine-tumors
#4
REVIEW
Lisa Bodei, Jarosław B Ćwikla, Mark Kidd, Irvin M Modlin
Bronchopulmonary (BP) neuroendocrine tumors (NETs) comprise a spectrum of tumors that develop from respiratory neuroendocrine cells and represent ~20% of all lung neoplasia and ~30% of all NETs. The only curative treatment is surgical resection. For well-differentiated forms (typical and atypical carcinoids), medical therapy ranges from bioactive agents (e.g., somatostatin analogs), to biotherapy (e.g., everolimus), standard chemotherapy and peptide receptor radionuclide therapy (PRRT). PRRT with radiolabeled somatostatin analogs is an innovative treatment for inoperable or metastasized, well/moderately differentiated, NET...
November 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29176078/one-stage-surgery-for-synchronous-liver-metastasis-from-a-neuroendocrine-tumor-of-the-colon-a-case-report
#5
Nicola Tartaglia, Alessandra Di Lascia, Pasquale Cianci, Alberto Fersini, Francesca Sanguedolce, Roberta Iadarola, Sabino Capuzzolo, Vincenzo Neri, Antonio Ambrosi
INTRODUCTION: Neuroendocrine tumors (NETs) are a heterogeneous group of tumors. NET of colon represent less than 1% of colonic tumors. Synchronous liver metastases, present in 75-80%, are considered significant adverse prognostic indicators. Liver is the second commonest site for metastasis in patients with colorectal neuroendocrine tumors. Available treatment options include surgical resection, chemotherapy, biotherapy. Surgery is the gold standard for curative therapy and it is strictly related to the localization, the grade of tumor, and the stage of disease...
November 20, 2017: Annali Italiani di Chirurgia
https://www.readbyqxmd.com/read/29171393/characterization-of-skin-th17-transcriptional-profiles-in-psoriatic-patients-under-adalimumab-biotherapy
#6
Amandine Buffiere-Morgado, Elodie Couderc, Adriana Delwail, Laure Favot, Jean-François Jegou, Elisabeth Solau, Gérard Guillet, Jean-Claude Lecron, Frank Morel
In psoriasis, a specific cytokine network has been described to play a central role in the pathophysiology of the disease. Anti-cytokine therapeutic approaches have been largely developed and TNFα constitutes the main target. Adalimumab is a human anti-TNFα monoclonal antibody that has been reported to demonstrate clinical efficacy and safety, resulting in reversal of epidermal hyperplasia and cutaneous inflammation. We aimed to analyse changes in the skin inflammatory transcriptomic profile in psoriatic patients during adalimumab therapy...
November 24, 2017: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/29149127/percutaneous-nephrostomy-infusion-nursing-considerations-for-treatment-of-upper-urinary-tract-urothelial-carcinoma
#7
Eryn Draganski, Ellen Sterman, Kathy Morris
An intrarenal approach using a percutaneous nephrostomy tube is a novel method to deliver chemotherapy and biotherapy to patients with upper urinary tract urothelial carcinoma. A paucity of evidence exists regarding basic nursing implications for this unique treatment option. This column will provide suggested guidelines to administer intrarenal treatment via a percutanous nephrostomy tube.
.
December 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/29078809/mesenchymal-stem-cells-for-cardiac-repair-are-the-actors-ready-for-the-clinical-scenario
#8
REVIEW
Santiago Roura, Carolina Gálvez-Montón, Clémentine Mirabel, Joaquim Vives, Antoni Bayes-Genis
For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches...
October 27, 2017: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/29069935/trastuzumab-modified-dm1-loaded-nanoparticles-for-her2-breast-cancer-treatment-an-in-vitro-and-in-vivo-study
#9
Ling Rong, Shuping Zhou, Xinkuang Liu, Amin Li, Tao Jing, Xueke Liu, Yinci Zhang, Shiyu Cai, Xiaolong Tang
BACKGROUND: Emtansine (DM1) is a highly potent anti-microtubule agent that has shown promising results for breast cancer treatment, but side effects limit its widespread clinical use. In this research, a new nano-drug was developed to integrate DM1 agent with antibody targeting. METHODS: A system of novel nanoparticles (NPs) DM1-NPs-trastuzumab (DM1-NPs-Tmab) of DM1 combined with (anti-HER2 antibody, Herceptin®, Trastuzumab) was developed for HER2(+) breast cancer treatment, and its physical characterization and antitumor biological activity were investigated...
October 25, 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/29067958/magnetic-resonance-gd-rgd-imaging-study-of-hepatocellular-carcinoma-with-high-and-low-metastatic-potential-before-and-after-human-bone-marrow-derived-mesenchymal-stem-cell-intervention
#10
Tian-Ran Li, Ming-Hui Yu, Xiao-Bin Huang, Zhi-Jie Yang, Guang-Ming Lu, Yan-Jun Li
BACKGROUND: Biotherapy based on human bone marrow-derived mesenchymal stem cells (BMSCs) is currently the focus of research, especially in the field of autologous stem cell transplantation. A novel type of metastasis-associated magnetic resonance (MR) molecular imaging probe was constructed, and the changes in metastasis and proliferation of hepatocellular carcinoma (HCC) before and after BMSC intervention were observed through MR imaging (MRI). METHODS: Metastasis-associated MR molecular imaging probe, integrin αvβ3ligand cRGD-PEG-DGL-DTPA-Gd (Gd-RGD), were constructed...
November 5, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/29067877/somatostatin-analogs-in-the-treatment-of-neuroendocrine-tumors-current-and-emerging-aspects
#11
Gherardo Mazziotti, Alessandra Mosca, Stefano Frara, Giovanni Vitale, Andrea Giustina
Neuroendocrine tumors (NETs) harbor somatostatin receptors and there is a strong rationale for using somatostatin analogs (SSAs) for treatment of NETs. Areas covered: This article discusses i) pharmacology of somatostatin and its analogs; ii) antisecretory and anti-proliferative effects of SSAs in NETs; iii) efficacy and safety of emerging therapeutic regimens with first generation SSAs administered at either high doses or in combination with antineoplastic drugs; iv) efficacy and safety of pasireotide and chimeric molecules; v) efficacy of radionuclide therapy of NETs using SSAs...
October 25, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28987810/chronic-rhinosinusitis-in-asia
#12
Yuan Zhang, Elien Gevaert, Hongfei Lou, Xiangdong Wang, Luo Zhang, Claus Bachert, Nan Zhang
Chronic rhinosinusitis (CRS), although possibly overdiagnosed, is associated with a high burden of disease and is often difficult to treat in those truly affected. Recent research has demonstrated that inflammatory signatures of CRS vary around the world, with less eosinophilic and more neutrophilic inflammation found in Asia compared with Europe and North America. Although in the Western world about 80% of nasal polyps carry a type 2 signature, this might be between 20% and 60% in China and Korea or Thailand, respectively...
October 4, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28973818/incremental-costs-in-giant-cell-arteritis
#13
Michael Mounié, Nadège Costa, Laurent Sailler, Maryse Lapeyre-Mestre, Robert Bourrel, Nicolas Savy, Laurent Molinier, Grégory Pugnet
OBJECTIVES: To assess and compare direct costs between giant cell arteritis (GCA) patients and matched-controls and identify incremental cost drivers. METHODS: We carried out a population-based, retrospective, cohort study using the French National Health Insurance System Database. Cost analysis was performed from the French health insurance perspective and took into account direct medical and non-medical costs (€, 2014). Costs were evaluated according to different cost components and divided into periods of 6 months for the accurate assessment of care consumption...
October 3, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28965131/efficacy-of-tocilizumab-highlighted-by-fdg-pet-ct-in-a-patient-with-relapsing-polychondritis-associated-aortitis
#14
REVIEW
Ghassan Elourimi, Michael Soussan, Ursula Warzocha, Hélène Bugaud, Robin Dhôte, Sébastien Abad
Relapsing polychondritis (RP) is a rare systemic inflammatory disease primarily affecting the ears, nose and tracheobronchial tree cartilage, but also the cardiovascular system. Cardiovascular complications are the second cause of mortality in RP. We report the case of a woman with a corticosteroid-resistant RP-associated aortitis, who was successfully treated with tocilizumab (TCZ). The FDG-PET/CT was a useful tool for diagnosing aortitis and assessing the effect of biotherapy. We conducted a systematic literature review confirming this is the first case of rapid and sustained remission in a patient with corticosteroid-resistant RP-associated aortitis after TCZ treatment administered as a first-line immunotherapy...
November 2017: Rheumatology International
https://www.readbyqxmd.com/read/28922238/primary-central-nervous-system-lymphoma-time-for-diagnostic-biomarkers-and-biotherapies
#15
Louis Royer-Perron, Khê Hoang-Xuan, Agusti Alentorn
PURPOSE OF REVIEW: Primary central nervous system lymphoma (PCNSL) is a rare cancer with a somber prognosis in older patients, which it affects predominantly. Only in recent years have molecular alterations characterizing PCNSL been thoroughly described. This opens possibilities for the use of targeted therapies. Developments in imaging and biomarkers have also great potential to help clinicians faced with diagnostic and prognostic uncertainties. RECENT FINDINGS: Several biomarkers for PCNSL, such as different microRNAs, which could be tested in cerebrospinal fluid and vitreous fluid, and IL-10, which has been shown to have excellent sensitivity and specificity in the cerebrospinal fluid, have emerged in the last years...
December 2017: Current Opinion in Neurology
https://www.readbyqxmd.com/read/28901727/retention-rates-of-adalimumab-etanercept-and-infliximab-as-first-line-biotherapy-agent-for-rheumatoid-arthritis-patients-in-daily-practice-auvergne-experience
#16
Martin Soubrier, Bruno Pereira, Thomas Frayssac, Angelique Fan, Marion Couderc, Sandrine Malochet-Guinamand, Sylvain Mathieu, Zuzana Tatar, Anne Tournadre, Jean-Jacques Dubost
OBJECTIVE: To compare, in real-life conditions, the retention rates of anti-tumor necrosis factor (anti-TNF) treatment (etanercept [ETN], adalimumab [ADA] and infliximab [IFX]) initiated as first-line biotherapy for rheumatoid arthritis (RA) and to evaluate, in case of failure, the switch to another anti-TNF or a non-anti-TNF biological. METHODS: Monocentric retrospective cohort including all patients with RA starting a first anti-TNF between 2001 and 2015. RESULTS: Among the 346 patients analyzed, 201 received ETN, 82 ADA and 63 IFX...
September 13, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28877634/certolizumab-an-anti-tnf-safe-during-pregancy-the-crib-study-results-an-interview-with-professor-xavier-mariette
#17
Xavier Mariette
Professor Xavier Mariette, MD, PhD, has served as the Head of the Rheumatology Department of Bicêtre Hospital, Paris-Sud University since 1999, a role he took following 10 years of practice of clinical immunology. Professor Mariette has initiated a number of clinical research studies on biotherapies in autoimmune diseases. He is the head of the French RATIO (Research Axed on Tolerance of Biotherapy) observatory, collecting specific rare serious adverse events in patients treated with anti-TNF. He initiated the French AIR (Autoimmunity and Rituximab) and ORA (Orencia and Rheumatoid arthritis) registries of patients with autoimmune diseases treated with rituximab and abatacept...
September 2017: Immunotherapy
https://www.readbyqxmd.com/read/28863429/biotherapies-and-biomarkers-for-cardiovascular-diseases-a-15-year-journey-at-the-icrec-heart-failure-and-cardiac-regeneration-research-laboratory-in-barcelona-spain
#18
Santiago Roura, Carolina Gálvez-Montón, Josep Lupón, Antoni Bayes-Genis
No abstract text is available yet for this article.
June 14, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28840372/persistent-perineal-sinus-after-abdominoperineal-resection
#19
Amélie Chau, Mathieu Prodeau, Hélène Sarter, Corinne Gower, Moshe Rogosnitzky, Yves Panis, Philippe Zerbib
BACKGROUND AND AIMS: Persistent perineal sinus (PPS) defined as a perineal wound remaining unhealed more than 6 months after abdominoperineal resection (APR) is a well-known complication. The aim of our study was (1) to evaluate the incidence of PPS after APR for Crohn's disease (CD) in the era of biotherapy, (2) to determine long-term outcome of PPS, (3) to study risk factors associated with delayed perineal healing, and (4) to compare the results in this CD patient group with patients without CD...
November 2017: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/28805478/production-of-platelet-rich-plasma-gel-from-elderly-patients-under-antithrombotic-drugs-perspectives-in-chronic-wounds-care
#20
M Velier, J Magalon, A Daumas, M Cassar, P Francois, A Ghazouane, C Philandrianos, B Bertrand, C Frere, D Bernot, P Villani, F Dignat George, F Sabatier
Platelet-Rich Plasma (PRP) is an autologous biological therapy obtained by centrifuging the patient's own blood to concentrate platelets. The addition of autologous thrombin and calcium chloride to PRP allows the production of a semi-solid form called PRP gel. PRP gel is increasingly used in a variety of tissue defects and predominantly in the management of non-healing chronic wounds. The topical application of PRP gel seems promising due to the capability of platelets to store and secrete growth factors (GF), fibrin and cytokines, which are essentials for wound healing...
August 14, 2017: Platelets
keyword
keyword
60436
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"